medigraphic.com

2007, Number S1

<< Back Next >>

Arch Cardiol Mex 2007; 77 (S1)

4. Medical and pharmacologic treatment according the etiology in the heart failure

Lorenzo NJA, López RMC, Verdejo PJ, Méndez OA, Pastelín HGS, Lomelí EC, González-Hermosillo GJA

Language: Spanish
References: 32
Page: 39-46
PDF size: 70.75 Kb.


Text Extraction

No abstract


REFERENCES

  1. WALSH CR, LARSON MG, EVANS JC, ET AL: Alcohol consumption and risk for congestive heart failure in The Framingham Heart Study. Ann Intern Med 2002; 136: 181-191.

  2. ABRAMSON JL, WILIAMS SA, KRUMHOLZ HM, VACARINO V: Moderate Alcohol consumption and risk of heart failure among older persons. JAMA 2001; 285: 1971-1977.

  3. COHN JN: The Management of chronic heart failure. N Engl J Med 1996; 335: 490-497.

  4. ANJU N, ELDRIN L, LYME WS: Medical Management of Advanced Heart Failure. JAMA 2002; 287: 628-638.

  5. WILHELMSEN L, ROSENGREN A, ERIKSON H, LAPPAS G: Heart failure in the general population of men: morbidity, risk factors and prognosis. J Intern Med 2001; 249: 253-261.

  6. CHOBANIAN AV, BAKRIS GL, BLACK HR, ET AL: Seventh report of the Joint National Committee on Prevention, Detection, evaluation and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.

  7. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 (published erratum appears in BMJ 1999; 318:29). BMJ 1998; 317: 703-713.

  8. KEREIAKES DJ, WILLERSON JT: Metabolic syndrome epidemic. Circulation 2003, 24: 1019- 1034.

  9. DORMANS TP, VAN MEYEL JJ, GERLAG PG, TAN Y, ET AL: Diuretic efficacy of high dose furosemide in severe Heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996; 28: 376-382.

  10. RALES Study. PITT B, ZANNAD E, REMME W ET AL: For the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999: 709-717.

  11. SABBAH HN, GOLDSTEIN S: Ventricular remodelating: consequences and therapy. Eur Heart J 1993; 14(Suppl.C): 24-29.

  12. PFEFFER MA, BRAUNWALD E, MOYE LA, ET AL: The effect of captopril on mortality with left ventricular dysfunction following myocardial infarction: Results of the survival and ventricular enlargement (SAVE) trial. N Engl J Med 1992; 327: 669-677.

  13. PFEFFER, ET AL: CHARM Trial. Lancet 2003; 362: 759-766.

  14. MCMURRAY JJ, OSTERGREN J, SWEDBERG K: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71.

  15. PACKER M, BRISTOW MR, COLIN JN: Effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-1355.

  16. GILBERT EM, OLSEN SL, RENHUND DG: Beta adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol 1993; 71: (Suppl.I): 12C-22C.

  17. The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in heart failure. N Engl J Med 1997; 336: 525-533.

  18. J.N. COHN,VAL-HEFT efficacy subgroup analyses (presentation). US Food and Drug Administration Web site. Available at www.fda.gov/ohrms/ dockets/ac/01/slides/3793s1_03_efficacy%20 subgroups.pdf.

  19. GOLDSMITH SR: Vasopressin: a therapeutic target in congestive heart failure. J Cardiac Fail 1999; 5: 347-56.

  20. GHEORGHIADE M, NIAZI I, OUYANG J, ET AL: Vasopressin V2 receptor Blockade with Tolvaptan in patients With Chronic Heart failure. Results from a Double Blind Randomized trial. Circulation 2003; 107: 2690-2696.

  21. TORRE-AMIONE G, KAPADIA S, LEE J, BIES RD, LEBOVITZ R, MANN DL: Expression and functional significance of tumor necrosis factor receptors human myocardium. Circulation 1995; 92: 1487-1493.

  22. GULLESTAD L, SEMB AG, HOLT E, ET AL: Effect of thalidomide in patients with chronic heart failure. Am Heart J 2002; 144: 847-850.

  23. OSTERZIELKJ, STROHM O, SCHLER J, ET AL: Randomized, double-blind placebo controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 1998; 351: 1233-1237.

  24. ANKER SD, VOLTERRANI M, ET AL: Acquired growth hormone resistance in patients with chronic heart failure. Implications for therapy with growth hormone. J Am Coll Cardiol 2001; 38: 443-452.

  25. ROULEAU JL, PFEFFER MA, STEWART DJ, ET AL: Comparison of vasopeptidase inhibitor omapatrilat and lisinopril on exercise tolerance and morbidity in patients with heart failure; IMPRESS randomized trial. Lancet 2000; 356(9230): 615-620.

  26. BAKER DW, WRIGHT RF: Management of heart failure: anticoagulation for patients with heart failure due to left ventricular systolic dysfunction. J Am Med Assoc 1994; 272: 1614-1618.

  27. AZUMA J, SAWAMURA A, AWATA N: Usefulness of taurine in chronic congestive heart failure and its prospective application. Jpn Circ J 1992; 56: 95-99.

  28. MILLER KL, LIEBOWITZ RS, NEWBY LK: Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches. Am Heart J 2004; 147: 401-411.

  29. REINOLD SC, RUTHERFORD JD: Peripartum cardiomyopathy. N Engl J Med 2001; 344: 21-30.

  30. BONNOW RO, CARABELLO BA, DE LEON AC, ET AL: Guidelines for the management of patients with valvular Heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 1998; 98: 1949-1984.

  31. IVERSEN PO, WOLBAEK PR, TONNESSEN T, ET AL: Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 2002; 282: R16-72.

  32. SILVERBERG DS, WEXLER D, BLOOM M, ET AL: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe resistant heart failure improves cardiac and renal function, functional cardiac class and markedly reduces hospitalization. J Am Coll Cardiol 2000; 35: 1737-1744.




2020     |     www.medigraphic.com